
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is in a strong position for growth with its diverse portfolio of generics, innovative medicines, and biosimilars in the neurology and immunology areas. With a solid presence in key markets such as North America and Europe, as well as potential for growth in emerging markets, the company has a strong foundation for long-term success. The recent acquisition of Emalex and the potential for a first-in-class D1 antagonist drug for the treatment of pediatric Tourette syndrome provide further potential for significant growth in the future. With continued focus on strategic BD and efficient allocation of capital, Teva has the potential to achieve significant revenue and profitability growth.
Bears say
Teva Pharmaceutical Indus is facing challenges in its generic drug business, as competition increases in the US market and the company faces patent expirations. The company's innovative portfolio and latest acquisition provide potential for growth, but execution remains crucial. While management is focused on cost savings and debt paydown to improve cash flows, there may be limited flexibility for large BD/M&A deals. Additionally, the recent court ruling on ProAir HFA patents could lead to competition for Teva's respiratory drugs, impacting sales.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares